Salvage therapy with single agent bendamustine for recurrent glioblastoma

Journal of Neuro-Oncology

Volumn 105, Issue 3, 2011, Pages 523-530

  Chamberlain, Marc C ^a   Johnston, Sandra K ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Bendamustine; Recurrent glioblastoma; Treanda

Indexed keywords

BENDAMUSTINE; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; IRINOTECAN; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECURRENT CANCER; SALVAGE THERAPY; STEREOTACTIC RADIOSURGERY; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITROGEN MUSTARD COMPOUNDS; SALVAGE THERAPY;

EID: 82955203749     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0612-7     Document Type: Article

References (41)

1. C Adamson OO Kanu, et al. 2009 Glioblastoma multiforme: a review of where we have been and where we are going Expert Opin Investig Drugs 18 8 1061 1083 19555299 10.1517/13543780903052764 1:CAS:528:DC%2BD1MXosFCmur4%3D
2. H Brem S Piantadosi PC Burger M Walker R Selker, et al. 1995 Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas Lancet 345 1008 1012 7723496 10.1016/S0140-6736(95)90755-6 1:STN:280: DyaK2M3ktVansw%3D%3D
3. SE Fogh DW Andrews J Glass, et al. 2010 Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas J Clin Oncol 28 18 3048 3053 20479391 10.1200/JCO.2009.25.6941
4. KA Carson SA Grossman, et al. 2007 Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials J Clin Oncol 25 18 2601 2606 17577040 10.1200/JCO.2006.08.1661 (Pubitemid 47041234)
5. ER Gerstner DG Duda, et al. 2007 Antiangiogenic agents for the treatment of glioblastoma Expert Opin Investig Drugs 16 12 1895 1908 18041999 10.1517/13543784.16.12.1895 1:CAS:528:DC%2BD2sXhtlGmu77J (Pubitemid 351418892)
6. LCA Hou A Veeravagu, et al. 2006 Recurrent glioblastoma multiforme: a review of natural history and management options Neurosurg Focus 20 4 E5 16709036 10.3171/foc.2006.20.4.2
7. WKA Yung L Mechtler MJ Gleason 1991 Intravenous carboplatin for recurrent malignant gliomas: a phase II study J Clin Oncol 9 860 1849986 1:STN:280:DyaK3M3gt1aitg%3D%3D
8. FM Iwamoto HA Fine 2010 Bevacizumab for malignant gliomas Arch Neurol 67 3 285 288 20212225 10.1001/archneurol.2010.11
9. DA Reardon KL Fink T Mikkelsen, et al. 2008 Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme J Clin Oncol 26 34 5610 5617 18981465 10.1200/JCO.2008.16.7510 1:CAS:528:DC%2BD1MXmsVSrsw%3D%3D
10. F Schmidt J Fischer U Herrlinger, et al. 2006 PCV chemotherapy for recurrent glioblastoma Neurology 66 4 587 589 16505319 10.1212/01.wnl. 0000197792.73656.c2 1:CAS:528:DC%2BD28XhtFeis7g%3D (Pubitemid 43739895)
11. L Simpson E Galanis 2006 Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates Expert Rev Anticancer Ther 6 11 1593 1607 17134364 10.1586/14737140.6.11.1593 1:CAS:528:DC%2BD2sXmvF2jtg%3D%3D (Pubitemid 44883962)
12. W Wick VK Puduvalli MC Chamberlain, et al. 2010 Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma J Clin Oncol 28 7 1168 1174 20124186 10.1200/JCO.2009.23.2595 1:CAS:528:DC%2BC3cXktF2ltb4%3D
13. A Wick C Pascher W Wick, et al. 2009 Rechallenge with temozolomide in patients with recurrent gliomas J Neurol 256 5 734 741 19240962 10.1007/s00415-009-5006-9 1:CAS:528:DC%2BD1MXmtVKmsro%3D
14. SJ See VA Levin A Yung, et al. 2004 13-cis-Retinoic acid in the treatment of recurrent glioblastoma multiforme Neuro-Oncology 6 253 258 15279718 10.1215/S1152851703000607 1:CAS:528:DC%2BD2cXmsl2rsLw%3D (Pubitemid 39136508)
15. MC Chamberlain D Tsao-Wei 2004 Recurrent glioblastoma multiforme: salvage therapy with cyclophosphamide Cancer 100 1213 1220 15022289 10.1002/cncr.20072 1:CAS:528:DC%2BD2cXivFagtr8%3D (Pubitemid 38325950)
16. KA Jaeckle KR Hess A Yung, et al. 2003 Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study J Clin Oncol 21 2305 2311 12805331 10.1200/JCO.2003.12.097 1:CAS:528: DC%2BD2cXpsVKjsrg%3D (Pubitemid 46621868)
17. DA Reardon PY Wen A Desjardins TT Batchelor JJ Vredenburgh 2008 Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy Expert Opin Biol Ther 8 4 541 553 18352856 10.1517/14712598.8.4.541 1:CAS:528: DC%2BD1cXjsFWkurs%3D (Pubitemid 351570416)
18. WK Yung RE Albright J Olson, et al. 2000 A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse Br J Cancer 83 5 588 593 10944597 10.1054/bjoc.2000.1316 1:CAS:528: DC%2BD3cXmvVCgsrs%3D (Pubitemid 30636298)
19. SE Coombs M Bischof T Welzel, et al. 2008 Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas J Neurooncol 89 2 205 210 10.1007/s11060-008-9607-4
20. PY Wen S Kesari 2008 Malignant gliomas in adults N Engl J Med 359 492 507 18669428 10.1056/NEJMra0708126 1:CAS:528:DC%2BD1cXpt1Sgsrw%3D
21. Park JK, Hodges T, Arko L. et al (2009) Scale to predict survival after surgery for recurrent glioblastoma multiforme. Presented in part at the Annual Meeting of the Congress of Neurological Surgeons, New Orleans, 24-29 October 2009
22. M Brada S Stenning R Gabe, et al. 2010 Temozolomide versus procarbazine, lomustine and vincristine in recurrent high-grade glioma J Clin Oncol 28 4601 4608 20855843 10.1200/JCO.2009.27.1932 1:CAS:528:DC%2BC3cXhsFaitLzP
23. DA Reardon KL Fink T Mikkelsen, et al. 2008 Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme J Clin Oncol 26 5610 5617 18981465 10.1200/JCO.2008.16.7510 1:CAS:528:DC%2BD1MXmsVSrsw%3D%3D
24. LB Nabors T Mikkelsen SS Rosenfeld, et al. 2007 Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma J Clin Oncol 25 13 1651 1657 17470857 10.1200/JCO.2006.06.6514 1:CAS:528: DC%2BD2sXlvFyktLY%3D (Pubitemid 46797943)
25. JR Perry K Belanger WP Mason, et al. 2010 Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE Study J Clin Oncol 28 12 2051 2057 20308655 10.1200/JCO.2009.26.5520 1:CAS:528: DC%2BC3cXmtlSksrk%3D
26. KV Ballman JC Buckner PD Brown, et al. 2007 The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme Neuro-Oncology 9 29 38 17108063 10.1215/15228517-2006-025 1:CAS:528:DC%2BD2sXht1Ojs7w%3D (Pubitemid 46543486)
27. KR Lamborn AWK Yung SM Chang, et al. 2008 Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas J Neurooncol 10 162 170
28. ET Wong KR Hess MJ Gleason, et al. 1999 Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials J Clin Oncol 17 2572 2578 10561324 1:STN:280:DC%2BD3c%2FjtVSmsQ%3D%3D (Pubitemid 29368260)
29. Bendamustine hydrochloride (CEP-18083) INVESTIGATOR'S BROCHURE, Cephalon Edition 2 Release Date: 4 March 2010
30. MJ Keating C Bach U Yasothan P Kirkpatrick 2008 Bendamustine Nat Rev Drug Discov 7 6 473 474 18511926 10.1038/nrd2596 1:CAS:528:DC%2BD1cXmsVOjsbc%3D (Pubitemid 351767115)
31. LM Leoni B Bailey J Reifert, et al. 2008 Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents Clin Cancer Res 14 1 309 317 18172283 10.1158/1078-0432.CCR-07-1061 1:CAS:528:DC%2BD1cXoslKk (Pubitemid 351378007)
32. W Köster G Stamatis A Heider, et al. 2004 Carboplatin in combination with bendamustine in previously untreated patients with extensive-stage small cell lung cancer (SCLC) Clin Drug Investig 24 10 611 618 17523723 10.2165/00044011-200424100-00007 (Pubitemid 44283969)
33. W Köster A Heider N Niederle, et al. 2007 Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer J Thorac Oncol 2 4 312 316 17409803 10.1097/01.JTO.0000263714.46449.4c (Pubitemid 47181714)
34. MH Eichbaum F Schuetz T Khbeis, et al. 2007 Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study Anticancer Drugs 18 8 963 968 17667603 1:CAS:528: DC%2BD2sXotlentLw%3D (Pubitemid 47220716)
35. JW Friedberg P Cohen L Chen, et al. 2008 Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study J Clin Oncol 26 2 204 210 18182663 10.1200/JCO.2007.12.5070 1:CAS:528:DC%2BD1cXitVWit70%3D
36. T Lissitchkov G Arnaudov D Peytchev KH Merkle 2006 Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy J Cancer Res Clin Oncol 132 2 99 104 16292542 10.1007/s00432-005-0050-z 1:CAS:528:DC%2BD2MXht1Oqsb7L (Pubitemid 41752051)
37. JW Friedberg P Cohen L Chen, et al. 2008 Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study J Clin Oncol 26 2 204 210 18182663 10.1200/JCO.2007.12.5070 1:CAS:528:DC%2BD1cXitVWit70%3D
38. K Zulkowski R Kath R Semrau KH Merkle K Höffken 2002 Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine J Cancer Res Clin Oncol 128 111 113 11862482 10.1007/s00432-001-0303-4 1:CAS:528:DC%2BD38XjvFCktQ%3D%3D (Pubitemid 34117834)
39. DR MacDonald TL Cascino SC Schold, et al. 1990 Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1277 1280 2358840 1:STN:280:DyaK3c3ptlyitQ%3D%3D (Pubitemid 20195640)
40. PY Wen DR Macdonald DA Reardon, et al. 2010 Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group J Clin Oncol 28 11 1963 1972 20231676 10.1200/JCO.2009.26.3541
41. BD Cheson M Rummel 2009 Bendamustine: rebirth of an old drug J Clin Oncol 27 9 1492 1501 19224851 10.1200/JCO.2008.18.7252 1:CAS:528:DC%2BD1MXksF2hsL8%3D